Skip to content
Back to Blog
Bio
2026-05-068 min read20

K-AI Drug Discovery Federated Learning Model Program: Strategic Use of the 37.1B KRW Government R&D

An analysis of Korea's 37.1B KRW K-AI Drug Discovery Federated Learning Program led by MOHW, with consortium participation and IP negotiation strategies for SME bio companies.

KITIM Consulting Team

1. Overview of the K-AI Drug Discovery Federated Learning Program

The K-AI Drug Discovery Federated Learning Model Program, launched by Korea's Ministry of Health and Welfare in 2026, is a major national R&D initiative that introduces artificial intelligence and federated learning into drug discovery at full scale.

  • Duration: 4 years 3 months (2026–2030)
  • Total Government Funding: Approximately 37.1 billion KRW (avg. 8.7 billion KRW/year)
  • Lead Agency: Ministry of Health and Welfare
  • Goal: Develop AI models for preclinical and clinical drug discovery using federated learning
  • Participants: Pharma/bio companies, hospitals, AI/data firms, research institutes
  • The program's strategic focus is not merely AI model development, but building a federated learning infrastructure that enables multi-institutional learning without moving sensitive medical data.

    2. How Federated Learning Transforms Drug Discovery

    Balancing Data Security and Learning Efficiency

    Traditional AI drug discovery required centralizing training data—nearly impossible under PIPA, GDPR, and HIPAA. Federated learning overcomes this barrier.

  • Local training, parameter-only sharing: Raw data stays within each institution
  • Differential Privacy: Additional security layer
  • Multi-institutional collaboration: Greater data volume and diversity, higher model accuracy
  • Acceleration and Success Rate Improvement

    Global benchmarks show federated learning–based drug discovery delivers:

  • 30–50% reduction in candidate discovery time
  • ~1.5x higher success rate in entering Phase 1 trials
  • 15–25 percentage point improvement in model accuracy versus single-institution data
  • Europe's MELLODDY consortium (10 global pharma companies) is a leading reference; K-AI aims to develop a Korean-adapted version.

    3. Participation Strategy for SME Bio Companies

    Consortium Formation and Role Positioning

    A 37.1B KRW program cannot be executed by a single firm—consortium formation (lead + joint + subcontracted) is required. SME bio companies can target these roles:

  • Joint research partner: Provide disease-specific data and clinical expertise
  • Subcontracted partner: AI model validation, candidate synthesis/evaluation
  • Demand-side participant: Apply developed models to proprietary pipelines
  • SMEs can leverage strengths in niche areas (rare diseases, specific indications, Korean-population-specific data) that differentiate them from large pharma and AI firms.

    Clinical Data Valuation and IP Negotiation

    Key to participation is data contribution valuation and IP allocation negotiation.

  • Quantitative valuation of clinical/preclinical data assets (volume, quality, rarity)
  • Pre-agreed equity share for trained models and discovered candidates
  • Royalty and milestone structuring for downstream commercialization
  • Data Use Agreement (DUA) execution
  • Leveraging Connected R&D Programs

    The K-AI program creates greater synergy when combined with other R&D initiatives:

  • MSIT AI Voucher Program (up to 300M KRW/year)
  • MOTIE Bio Industry Core Technology Program
  • MOHW Korea Drug Development Fund (KDDF)
  • MSS TIPS Bio/Health Track
  • 4. KITIM Consulting Services

    KITIM offers tailored consulting for bio companies considering participation:

  • Eligibility Assessment: Evaluation of data and technology assets, consortium positioning advisory
  • R&D Proposal Planning: Federated learning–based proposal writing, evaluation response
  • Consortium and Contract Advisory: Lead-agency matching, IP and data allocation negotiation
  • Technology Commercialization Strategy: Follow-on investment, technology transfer/licensing
  • Connected R&D Program Discovery: Multi-program roadmap (TIPS, KDDF, AI Voucher)
  • Participation in a 37.1B KRW national R&D program can be a defining inflection point for an SME bio company's technical leap and valuation. Systematic preparation and expert advisory are critical to success. If you are evaluating participation, please contact KITIM for consultation.

    K-AI Drug DiscoveryFederated LearningPreclinical-Clinical ModelBio R&DMOHW Program

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.